Uric Acid Serves as a Risk Factor or Marker for Developing Hypertension According to Both Conventional and Novel Definitions: An Association or Causation!

IF 2.7 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE
Ugur Canpolat
{"title":"Uric Acid Serves as a Risk Factor or Marker for Developing Hypertension According to Both Conventional and Novel Definitions: An Association or Causation!","authors":"Ugur Canpolat","doi":"10.1111/jch.70063","DOIUrl":null,"url":null,"abstract":"<p>In the current study, Liu et al. [<span>1</span>] assessed the relationship between serum uric acid (SUA) levels and incident hypertension at different blood pressure (BP) cut-off levels (140/90 and 130/80 mmHg) according to recent studies and guidelines. The study involved 26 973 participants from the Taiwan Biobank (TWB), who were followed for a median of 4 years. The association of hyperuricemia and sex with incident hypertension was significant for both traditional (140/90 mmHg) and new (130/80 mmHg) definitions. They also reported a significant interaction between hyperuricemia and sex. Although confounding factors in the prediction of incident hypertension (both for traditional and new definitions) were adjusted in the analyses, patients with incident hypertension revealed a higher rate of SUA-associated several comorbidities.</p><p>Hypertension is known as one of the major cardiovascular disease risk factors. It has both modifiable and non-modifiable pathophysiological mechanisms. Therefore, preventing and controlling hypertension by modifying underlying mechanisms is essential for public health [<span>2</span>]. Hyperuricemia is a well-known mediator for the development of cardiovascular diseases, including hypertension, by driving inflammation and oxidative stress [<span>3-5</span>]. Both genetic and environmental factors influence the complex pathogenesis of hyperuricemia and its link to hypertension [<span>6</span>]. The SUA level of &gt;7.0 mg/dL in males and &gt;6.0 mg/dL in females is defined as hyperuricemia [<span>7</span>]. Uric acid deposition-mediated endothelial dysfunction and vascular injury typically occur at SUA levels that exceed 6.5 mg/dL. However, this threshold is significantly higher than those reported in studies linking it to hypertension and cardiovascular disease [<span>6</span>]. Moreover, uric acid is a metabolic end product that fluctuates due to modifiable (diet, medications, etc.) and non-modifiable (genetics, age, etc.) factors. Therefore, it is unreasonable to establish a causal relationship between SUA levels and cardiovascular diseases, including hypertension, based on a single SUA measurement. Although most studies used baseline single SUA levels, it is essential to consider the temporal trends of this fluctuating variable. Kuwabara et al. [<span>8</span>] demonstrated that hyperuricemia in asymptomatic male and female subjects without cardiac and metabolic comorbidities is an independent risk factor for hypertension within 5 years. In another study, Salim et al. [<span>9</span>] also reported a significant association between hyperuricemia and sex with incident hypertension using different BP cut-offs (≥140/90 and ≥130/80 mmHg). Although the confounding factors or comorbidities have been adjusted before linking the SUA levels or hyperuricemia with incident hypertension in all those studies, they do not prove a direct causal relationship. Thus, there is a debate about hyperuricemia as either a causative risk factor or a bystander (risk marker) for hypertension and cardiovascular events. The statistics indicate that <i>the association is insufficient for causation</i>. In line with the limitations above, the effect of urate-lowering therapy on hypertension and cardiovascular outcomes has been heterogeneous in previous studies [<span>10-13</span>]. In the study by Liu et al. [<span>1</span>], no data were present about dietary factors and medications impacting SUA levels at baseline and follow-up. The study also lacks temporal trends in SUA levels and confounding risk factors that could be related to incident hypertension. As the study results confirmed the relation of male and female sex with hyperuricemia and incident hypertension, the data also lack the menopausal (natural or premature) status of the females in the study population. The predictive value of SUA quartiles with lower thresholds than the hyperuricemia definition on incident hypertension should also be considered when interpreting the study results. Based on the study by Liu et al. [<span>1</span>] and previous studies, future studies should use SUA level as a continuous variable rather than a standard hyperuricemia definition to predict incident hypertension or cardiovascular outcomes. Because of the direct relationship of SUA level to numerous comorbid conditions associated with hypertension, SUA level may be a <i>risk marker</i>, but <i>not a risk factor</i>, for incident hypertension.</p><p>Ugur Canpolat: Substantial contributions to the design of the manuscript; drafting the work and reviewing it critically for important intellectual content; final approval of the version to be published and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy of any part of the work are appropriately investigated and resolved.</p><p>The author has nothing to report.</p><p>The author declares no conflicts of interest.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"27 5","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jch.70063","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Hypertension","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jch.70063","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

In the current study, Liu et al. [1] assessed the relationship between serum uric acid (SUA) levels and incident hypertension at different blood pressure (BP) cut-off levels (140/90 and 130/80 mmHg) according to recent studies and guidelines. The study involved 26 973 participants from the Taiwan Biobank (TWB), who were followed for a median of 4 years. The association of hyperuricemia and sex with incident hypertension was significant for both traditional (140/90 mmHg) and new (130/80 mmHg) definitions. They also reported a significant interaction between hyperuricemia and sex. Although confounding factors in the prediction of incident hypertension (both for traditional and new definitions) were adjusted in the analyses, patients with incident hypertension revealed a higher rate of SUA-associated several comorbidities.

Hypertension is known as one of the major cardiovascular disease risk factors. It has both modifiable and non-modifiable pathophysiological mechanisms. Therefore, preventing and controlling hypertension by modifying underlying mechanisms is essential for public health [2]. Hyperuricemia is a well-known mediator for the development of cardiovascular diseases, including hypertension, by driving inflammation and oxidative stress [3-5]. Both genetic and environmental factors influence the complex pathogenesis of hyperuricemia and its link to hypertension [6]. The SUA level of >7.0 mg/dL in males and >6.0 mg/dL in females is defined as hyperuricemia [7]. Uric acid deposition-mediated endothelial dysfunction and vascular injury typically occur at SUA levels that exceed 6.5 mg/dL. However, this threshold is significantly higher than those reported in studies linking it to hypertension and cardiovascular disease [6]. Moreover, uric acid is a metabolic end product that fluctuates due to modifiable (diet, medications, etc.) and non-modifiable (genetics, age, etc.) factors. Therefore, it is unreasonable to establish a causal relationship between SUA levels and cardiovascular diseases, including hypertension, based on a single SUA measurement. Although most studies used baseline single SUA levels, it is essential to consider the temporal trends of this fluctuating variable. Kuwabara et al. [8] demonstrated that hyperuricemia in asymptomatic male and female subjects without cardiac and metabolic comorbidities is an independent risk factor for hypertension within 5 years. In another study, Salim et al. [9] also reported a significant association between hyperuricemia and sex with incident hypertension using different BP cut-offs (≥140/90 and ≥130/80 mmHg). Although the confounding factors or comorbidities have been adjusted before linking the SUA levels or hyperuricemia with incident hypertension in all those studies, they do not prove a direct causal relationship. Thus, there is a debate about hyperuricemia as either a causative risk factor or a bystander (risk marker) for hypertension and cardiovascular events. The statistics indicate that the association is insufficient for causation. In line with the limitations above, the effect of urate-lowering therapy on hypertension and cardiovascular outcomes has been heterogeneous in previous studies [10-13]. In the study by Liu et al. [1], no data were present about dietary factors and medications impacting SUA levels at baseline and follow-up. The study also lacks temporal trends in SUA levels and confounding risk factors that could be related to incident hypertension. As the study results confirmed the relation of male and female sex with hyperuricemia and incident hypertension, the data also lack the menopausal (natural or premature) status of the females in the study population. The predictive value of SUA quartiles with lower thresholds than the hyperuricemia definition on incident hypertension should also be considered when interpreting the study results. Based on the study by Liu et al. [1] and previous studies, future studies should use SUA level as a continuous variable rather than a standard hyperuricemia definition to predict incident hypertension or cardiovascular outcomes. Because of the direct relationship of SUA level to numerous comorbid conditions associated with hypertension, SUA level may be a risk marker, but not a risk factor, for incident hypertension.

Ugur Canpolat: Substantial contributions to the design of the manuscript; drafting the work and reviewing it critically for important intellectual content; final approval of the version to be published and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy of any part of the work are appropriately investigated and resolved.

The author has nothing to report.

The author declares no conflicts of interest.

根据传统和新定义,尿酸可作为发生高血压的危险因素或标志:关联或因果关系!
在本研究中,Liu等人根据最新研究和指南评估了不同血压(BP)截止水平(140/90和130/80 mmHg)下血清尿酸(SUA)水平与高血压发病的关系。本研究涉及台湾生物库(TWB)的26973名参与者,随访时间中位数为4年。无论是传统的(140/90 mmHg)还是新的(130/80 mmHg)定义,高尿酸血症和性行为与高血压事件的关联都是显著的。他们还报告了高尿酸血症与性之间的显著相互作用。虽然在分析中调整了预测高血压事件(传统和新定义)的混杂因素,但高血压事件患者显示出与sua相关的几种合并症的发生率更高。高血压被认为是心血管疾病的主要危险因素之一。它具有可改变和不可改变的病理生理机制。因此,通过改变潜在机制来预防和控制高血压对公共卫生至关重要。高尿酸血症是众所周知的心血管疾病,包括高血压,通过驱动炎症和氧化应激发展的中介[3-5]。遗传和环境因素影响高尿酸血症的复杂发病机制及其与高血压的关系。男性SUA水平为7.0 mg/dL,女性SUA水平为6.0 mg/dL,定义为高尿酸血症。尿酸沉积介导的内皮功能障碍和血管损伤通常发生在SUA水平超过6.5 mg/dL时。然而,这一阈值明显高于将其与高血压和心血管疾病联系起来的研究报告。此外,尿酸是一种代谢终产物,由于可改变(饮食、药物等)和不可改变(遗传、年龄等)因素而波动。因此,仅凭单一的SUA测量来建立SUA水平与包括高血压在内的心血管疾病之间的因果关系是不合理的。虽然大多数研究使用基线单一SUA水平,但必须考虑这一波动变量的时间趋势。Kuwabara等人证实,无心脏和代谢合并症的无症状男性和女性受试者的高尿酸血症是5年内高血压的独立危险因素。在另一项研究中,Salim等人使用不同的血压临界值(≥140/90和≥130/80 mmHg)也报道了高尿酸血症和性行为与高血压事件之间的显著关联。虽然在所有这些研究中,在将SUA水平或高尿酸血症与高血压事件联系起来之前,已经调整了混杂因素或合并症,但它们并没有证明直接的因果关系。因此,关于高尿酸血症是高血压和心血管事件的致病危险因素还是旁观者(风险标志)存在争议。统计表明,这种关联不足以形成因果关系。由于上述局限性,在以往的研究中,降尿酸治疗对高血压和心血管结局的影响存在异质性[10-13]。在Liu等人的研究中,没有关于饮食因素和药物在基线和随访时影响SUA水平的数据。该研究还缺乏SUA水平的时间趋势和可能与高血压事件相关的混杂危险因素。虽然研究结果证实了男性和女性与高尿酸血症和高血压的关系,但研究人群中女性的绝经(自然或过早)状态也缺乏数据。在解释研究结果时,还应考虑阈值低于高尿酸血症定义的SUA四分位数对高血压事件的预测价值。基于Liu等人的研究和先前的研究,未来的研究应该使用SUA水平作为一个连续变量,而不是标准的高尿酸血症定义来预测高血压事件或心血管结局。由于SUA水平与许多与高血压相关的合并症有直接关系,SUA水平可能是高血压事件的危险标志,但不是危险因素。Ugur Canpolat:对稿件设计有重大贡献;起草工作,并对重要的知识内容进行批判性审查;最终批准即将出版的版本,并同意对工作的各个方面负责,以确保与工作任何部分的准确性相关的问题得到适当的调查和解决。作者没有什么可报道的。作者声明无利益冲突。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Hypertension
Journal of Clinical Hypertension PERIPHERAL VASCULAR DISEASE-
CiteScore
5.80
自引率
7.10%
发文量
191
审稿时长
4-8 weeks
期刊介绍: The Journal of Clinical Hypertension is a peer-reviewed, monthly publication that serves internists, cardiologists, nephrologists, endocrinologists, hypertension specialists, primary care practitioners, pharmacists and all professionals interested in hypertension by providing objective, up-to-date information and practical recommendations on the full range of clinical aspects of hypertension. Commentaries and columns by experts in the field provide further insights into our original research articles as well as on major articles published elsewhere. Major guidelines for the management of hypertension are also an important feature of the Journal. Through its partnership with the World Hypertension League, JCH will include a new focus on hypertension and public health, including major policy issues, that features research and reviews related to disease characteristics and management at the population level.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信